08:00 , Mar 2, 2009 |  BC Week In Review  |  Company News

Cellatope Corp, Cypress Bioscience deal

Cypress acquired Cellatope's cell-bound complement activation products (CB-CAP) technology for $2 million in cash and $3 million in milestones. Cypress will use the technology to develop a blood-based CLIA test to diagnose and monitor treatment...